Ireland
--:--IST
Priya Life Science Medicines register
Registers› Irish medicines ›Lisinopril 1 mg/ml Oral Solution
Medicines register · Ireland

Lisinopril 1 mg/ml Oral Solution

Authorisation PA23081/013/001 · Taw Pharma (Ireland) Limited

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 21 Nov 2026
Licence holder
Taw Pharma (Ireland) Limited (all products →)
Active substance
Lisinopril Dihydrate
Dosage form
Oral solution
Route of administration
Oral use
ATC codes
C09AA, C09AA03
First authorised
31/07/2015
Prescription status
Product subject to prescription which may be renewed (B)
Supply
Supply through pharmacies only
Legal basis
Generic application (Article 10(1) of Directive No 2001/83/EC)

Lisinopril Dihydrate: supply and approvals

20 authorised products on the HPRA list contain Lisinopril Dihydrate. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 20 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 20 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 20 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 11 years (since 31 July 2015). The HPRA list marks it as not marketed: it is licensed but the holder has not reported it as on sale.

Other medicines with Lisinopril Dihydrate in Ireland

14 other products on the HPRA list contain Lisinopril Dihydrate, from 5 licence holders; 11 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Lisopress 10 mg tabletsGedeon Richter PlcNational authorisation (PA)Marketed
Lisopress 20 mg tabletsGedeon Richter PlcNational authorisation (PA)Marketed
Lisopress 5 mg tabletsGedeon Richter PlcNational authorisation (PA)Marketed
Lispril 5 mg TabletsRowex Limited,National authorisation (PA)Marketed
Lispril-Hydrochlorothiazide 10 mg/12.5 mg tabletsRowex Limited,National authorisation (PA)Marketed
Lispril-Hydrochlorothiazide 20 mg/12.5 mg tabletsRowex Limited,National authorisation (PA)Marketed
Zestan 10 mg tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Zestan 2.5mg TabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Zestan 20 mg tabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Zestan 5mg TabletsClonmel Healthcare LtdNational authorisation (PA)Marketed
Zestoretic 10 mg /12.5 mg TabletsAtnahs Pharma Netherlands B.V.National authorisation (PA)Marketed
Lisinopril Grindeks 10 mg tabletsAS GrindeksNational authorisation (PA)Not marketed

All 15 products with Lisinopril Dihydrate →

Other substances in ATC group C09AA

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 9 other active substances share the group C09AA with this product:

Ramipril (19) · Enalapril maleate (10) · Perindopril tert-butylamine (6) · Lisinopril (4) · Perindopril arginine (3) · Lisinopril (as dihydrate) (2) · Trandolapril (2) · Perindopril tosilate (2) · Zofenopril calcium (2)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Taw Pharma (Ireland) Limited holds 11 products on the HPRA list, with 14 different active substances; 6 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.